Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00247-002-0858-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atypical antipsychotic drug olanzapine inhibits 5-HT receptor-mediated currents by allosteric and non-competitive mechanisms.
Korean J Physiol Pharmacol
December 2024
Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Olanzapine, an atypical antipsychotic, is widely used in the treatment of schizophrenia and bipolar disorder due to its modulation of dopamine and serotonin receptor systems. While its primary action involves antagonism of dopamine D2 and serotonin 5-HT (5-hydroxytryptamine)A receptors, recent evidence suggests that olanzapine also inhibits 5-HT receptors, which are ligand-gated ion channels involved in synaptic transmission in central and peripheral nervous systems. The present study aimed to investigate the action of olanzapine on 5-HT receptor-mediated currents using whole-cell voltage-clamp recordings in NCB-20 neuroblastoma cells.
View Article and Find Full Text PDFQuetiapine competitively inhibits 5-HT receptor-mediated currents in NCB20 neuroblastoma cells.
Korean J Physiol Pharmacol
December 2024
Department of Pharmacology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
The 5-hydroxytryptamine type (5-HT) receptor, a ligand-gated ion channel, plays a critical role in synaptic transmission. It has been implicated in various neuropsychiatric disorders. This study aimed to elucidate the mechanism by which quetiapine, an atypical antipsychotic, could inhibit 5-HT receptor-mediated currents in NCB20 neuroblastoma cells.
View Article and Find Full Text PDFMetastatic Neuroblastoma Mimicking Multiple Infantile Hemangiomas Diagnosed With Ultrasound.
Cureus
November 2024
Dermatology, AdventHealth, Orlando, USA.
Neuroblastoma is a malignant tumor derived from the neural crest cells that often involves the adrenal glands and rarely metastasizes to the skin. Here, we present a case of a nine-month-old male infant who presented with multiple noncompressible blue-purple subcutaneous nodules, initially suggestive of atypical deep hemangiomas. The ultrasound revealed a lack of increased vascularity of the masses and an adrenal mass, leading to a biopsy and diagnosis of a neuroblastoma involving the adrenal gland, liver, and skin.
View Article and Find Full Text PDFCase Report of Dinutuximab-induced Atypical Hemolytic Uremic Syndrome.
J Pediatr Hematol Oncol
January 2025
Department of Pediatric Hematology and Oncology, Advent Health for Children, Orlando, FL.
Limited evidence exists describing the relationship between the development of atypical hemolytic uremic syndrome (aHUS) and the administration of dinutuximab. This case report describes a 20-year-old male with neuroblastoma who experienced aHUS post-dinutuximab administration. The patient presented with uncontrolled hypertension and renal dysfunction, ultimately receiving a definitive diagnosis of aHUS through a renal biopsy.
View Article and Find Full Text PDFManagement of Busulfan-Induced Lung Injury in Pediatric Patients with High-Risk Neuroblastoma.
J Clin Med
October 2024
Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany.
: Integrating the cytotoxic drug busulfan into a high-dose chemotherapy regimen prior to autologous hematopoietic stem cell rescue in patients with high-risk neuroblastoma has improved the survival of children battling this deadly disease. Busulfan-induced toxicities can, however, be severe. Here, we describe the diagnosis and successful treatment of acute pulmonary injury by total-body-weight-adjusted busulfan therapy in two children with high-risk neuroblastoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!